Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia

ABSTRACT: Acute myeloid leukemia (AML) is an aggressive malignancy that can only be cured by intensive therapy. However, many elderly and unfit patients cannot receive such treatment due to an unacceptable risk of treatment-related morbidity and mortality. Disease-stabilizing therapy is then the only possible strategy, one alternative being treatment based on all-trans retinoic acid (ATRA) combined with the histone deacetylase inhibitor valproic acid and possibly low-toxicity conventional chemotherapy.

ORGANISM(S): Homo sapiens

PROVIDER: GSE106096 | GEO | 2017/10/25

SECONDARY ACCESSION(S): PRJNA415597

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Identification differentially expressed genes upon valproic acid treatment

2011-07-13 | GSE30517 | GEO

Gene expression profile of the human leukemia cell line Reh after treatment with bortezomib, valproic acid or a combination of both.

Project description:New therapy options are required for relapsed B-cell precursor ALL patients in order to improve survival and reduce adverse acute and late effects. We observed a synergistic anti-leukemic activity of concomitant treatment with bortezomib and valproic acid in BCP-ALL cells. In this experiment we aimed to identify the pathways modulated after concomitant treatment with bortezomib and valproic acid. Reh cells treated with either bortezomib, valproic acid, or the combination of both normalized to a untreated control.

2013-02-01 | E-GEOD-41951 | biostudies-arrayexpress

Gene expression profile of the human leukemia cell line Reh after treatment with bortezomib, valproic acid or a combination of both.

2013-02-01 | GSE41951 | GEO

Genome-wide expression profiling after Valproic acid treatment in Saccharomyces cerevisiae

Project description:Valproic acid (VA) is a small-chain branched fatty acid, widely used as anticonvulsant, and mood stabilizer to treat psychiatric illness. Valproic acid is also known to inhibit the histone deacetylases (HDACs), which makes it as a potent antitumor agent in alone or in combination with other cytotoxic drugs. Beside its conventional activities, valproic acid reported to have much broader, complicated effects and affect many complex physiological processes. However the molecular mechanisms of valproic acid are unclear. So, we used budding yeast transcriptome analysis to better understand the molecular mechanism of action of valproic acid. The clusters of differentially expressed genes in microarray after VA (6mM) treatment and their functional enrichment analysis revealed its overall effects on various biological processes such as cell cycle, signal transduction, metabolism, transcription, ubiquitination, transporter activities and many more. The microarray data were validated by quantitative real-time PCR.

2016-10-14 | GSE62400 | GEO

Transcription profiling of human embryonic stem cells in response to valproic acid and valproic acid analogs

Project description:Transcriptional profiling of valproic acid and valproic acid analogs in human embryonic stem cells.

2010-12-31 | E-MEXP-2374 | biostudies-arrayexpress

Effect of Valproic Acid on Endothelial Cells

Project description:Valproic acid (VPA) is a short-chain fatty acid used in the treatment of epilepsy and also considered to be an epigenetic modifier by functioning as a histone deacetylase (HDAC)-inhibitor. The aim of this study was to search for gene altered by VPA in human endothelial cells.

2012-03-14 | GSE23909 | GEO

Responder and non-responder proteomic and phosphoproteomic profiles to ATRA/Valproic acid before treatment

Project description:Proteomic and phosphoproteomic raw files from responder and non-responder acute myeloid leukemia patient samples before initiation of ATRA/valproic acid treatment

2021-09-10 | PXD024110 | Pride

Identification differentially expressed genes upon valproic acid treatment

Project description:The goal of this study is to define genes that are differentially expressed in Down syndrome leukemic blasts after treatment with valproic acid (VPA) Here we report the identification gene sets that are downregulated in Down syndrome leukemic cell lines after exposure to valproic acid (VPA) CMK and CMY cells were treated with VPA for 24h and 48h with 1mM or 2mM VPA. Their gene expression profile was compared against the untreated control.

2011-07-12 | E-GEOD-30517 | biostudies-arrayexpress

Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia

Project description:Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia

| PRJNA415597 | ENA

Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer

Project description:The purpose of this study is to first determine the maximum tolerated dose of capecitabine given alone or in combination with valproic acid during preoperative short-course radiotherapy (Phase 1). The next part of the study (Phase 2)will explore whether the addition of valproic acid or the addition of capecitabine to short-course radiotherapy, before optimal radical surgery might increase the pathologic complete tumor regression rate in patients with low-moderate risk rectal cancer.

| 2148214 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data